Supernus Pharmaceuticals will acquire Sage Therapeutics in a deal worth up to $795 million, gaining access to the only postpartum depression pill approved in the United States, the companies said on ...

Notice of the Cambridge biotech's layoffs came less than two weeks after Sage announced it would be acquired by ...

Sage Therapeutics is laying off most of its employees after announcing its planned acquisition earlier this month.

Sage had 338 full-time employees, all of whom will be laid off effective Aug. 22. The layoffs were announced a few weeks ...

A Cambridge biotech company is preparing to lay off its entire staff of more than 300 after being acquired by another firm.

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

Two weeks after Supernus Pharmaceuticals unveiled the proposed acquisition of Sage Therapeutics, all 338 employees from the latter company are being canned, ...

Following a turbulent few years, Sage Therapeutics has been acquired by Maryland-based Supernus Pharmaceuticals for up to ...

Supernus Pharmaceuticals (NASDAQ:SUPN) has agreed to acquire depression drugmaker Sage Therapeutics (NASDAQ:SAGE) for a total consideration of up to $795M, or $12 per share, in an all-cash deal, the ...

Actress and talk show host Busy Philipps as well as sports reporter Jay Glazer have both headed up separate campaigns for Qelbree, a non-stimulant ADHD treatment manufactured by Supernus. This marks a ...

Supernus CEO Jack Khattar said the deal adds a “significant fourth growth product to our portfolio and further diversifies ...

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...